



# Global Health L i m i t e d

8<sup>th</sup> February, 2024

**Ref:-** GH/2023-24/EXCH/96

The General Manager  
Dept. of Corporate Services  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai - 400 001

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

**Scrp Code:** 543654

**Symbol:** MEDANTA

**Sub:** Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Dear Sir(s),

We would like to inform you that the Board of Directors of Global Health Limited ('GHL/Company') at its meeting held today i.e. *Thursday, February 8, 2024*, inter-alia, approved the Unaudited Standalone & Consolidated Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2023 ('Results').

The certified copies of Results along with Limited Review Reports from the Statutory Auditors M/s Walker Chandiook & Co LLP, Chartered Accountants thereon, are enclosed herewith as **Exhibit**, pursuant to Regulation 33 of the Listing Regulations.

Accordingly, the Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges.

Further, we would also like to inform you that, the Board at the aforesaid meeting, also approved the appointment of Mr. Yogesh Kumar Gupta, as Chief Financial Officer & Key Managerial Personnel of the Company with immediate effect.

The details as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are provided in **Annexure A**.

The meeting of the Board of Directors commenced at 2.30 P.M. and concluded at 4.05 P.M.

Thanking You,

**For Global Health Limited**

**Rahul Ranjan**  
Company Secretary & Compliance Officer

M. No. A17035



Encl: n/a

Disclosure pursuant to Regulation 30 of SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

1. Reason for change viz. appointment, ~~resignation, removal, death or otherwise~~: -Appointment
2. Date of appointment/re-appointment/~~cessation~~ (as applicable) & terms of appointment: February 8, 2024, he has been appointed as Full time Key Managerial Personnel and designated as Chief Financial Officer of the Company.
3. Disclosure of relationships between directors (in case of appointment of a director): Not Applicable
4. Brief profile (in case of appointment): Mr. Yogesh Kumar Gupta is a highly experienced and accomplished Chartered Accountant with a remarkable 27 year career in finance, accounting, and commercial management across diverse industries, including pharmaceutical manufacturing, retail, and healthcare.

Recently, he was working as Chief Financial Officer of Sheares Healthcare India and was responsible for overseeing various investee companies.

Under his leadership the Company underwent significant transformation, marked by strategic changes in management and operational processes, resulted in substantial improvement in both revenue and EBITDA.

Prior to this, he was associated with Max Healthcare Institute Limited as Sr. VP-Finance. He was responsible for transforming entire finance function from manual processes to digital finance function. His Key achievements are implementation of ERP, Workflows for expense approvals/vendor payments/employee expense reimbursements, Shared Service Center, Self Service Dashboards, Procedure level actual material cost sheets, Automation of management review reports and financial controls. He performed the role of controller for the group and undertake responsibilities includes handing of financial books closure and statutory reporting for 15 legal entities. He has also handled Bank and treasury, Direct and Indirect tax and Insurance Programs of the Companies.

During his career journey, he was also a vital part of various organisations such as Fortis Healthcare, TPG Wholesale Private Limited, Reliance Retail Ltd, Ranbaxy Laboratories Limited etc.

*Ranjan*



---

Walker ChandioK & Co LLP  
21st Floor, DLF Square  
Jacaranda Marg, DLF Phase II  
Gurugram - 122 002  
India

T +91 124 462 8099  
F +91 124 462 8001

**Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Global Health Limited**

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Global Health Limited ('the Company') for the quarter ended 31 December 2023 and the year to date results for the period 01 April 2023 to 31 December 2023, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



---

Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

---

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

## Walker ChandioK & Co LLP

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker ChandioK & Co LLP  
Chartered Accountants  
Firm Registration No: 001076N/N500013

*Tarun*

Tarun Gupta  
Partner  
Membership No. 507892

UDIN: 24507892BKEISE2665

Place: Gurugram  
Date: 08 February 2024



Global Health Limited

Registered Office: Medanta MedClinic, E-18, Defence Colony, New Delhi - 110024, India  
Corporate Office: Medanta - The Medicity, Sector - 38, Gurgaon, Haryana - 122001, India  
CIN: L85110DL2004PLC128319

Tel: +91124 483 4060; E-mail: [compliance@medanta.org](mailto:compliance@medanta.org); Website: <https://www.medanta.org>

Statement of Standalone Unaudited Financial Results for the quarter ended and nine months period ended 31 December 2023

(₹ in lakhs, unless otherwise stated)

S No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31 December 2023 (Unaudited)	30 September 2023 (Unaudited)	31 December 2022 (Unaudited)	31 December 2023 (Unaudited)	31 December 2022 (Unaudited)	31 March 2023 (Audited)
	<b>Income</b>						
I	Revenue from operations	56,167.76	58,014.64	48,978.60	168,641.20	145,653.63	195,944.62
II	Other income	2,583.34	2,623.53	1,252.29	8,527.13	3,358.08	6,168.29
	<b>Total income</b>	<b>58,751.10</b>	<b>60,638.17</b>	<b>50,230.89</b>	<b>177,168.33</b>	<b>149,011.71</b>	<b>202,112.91</b>
	<b>III Expenses</b>						
	Cost of materials consumed	12,544.65	12,657.01	10,634.67	37,235.12	31,762.99	43,010.47
	Purchases of stock-in-trade	1,011.13	1,112.57	815.21	3,238.69	2,530.82	3,590.34
	Changes in inventories of stock-in-trade	51.84	3.67	95.40	(46.50)	149.51	(40.65)
	Employee benefits expense	14,711.64	14,858.42	13,360.63	44,142.32	40,035.65	53,163.41
	Finance costs	575.90	610.60	649.22	1,824.64	1,978.24	2,616.14
	Depreciation and amortisation expense	2,173.02	2,154.24	2,161.56	6,370.06	6,573.44	8,608.86
	Impairment losses on financial assets	507.90	553.07	275.12	1,695.09	467.77	746.24
	Retainers and consultants fee	6,054.21	5,791.30	4,503.04	17,318.42	13,424.28	18,417.81
	Other expenses	9,033.60	10,208.02	9,746.67	29,040.17	27,337.89	36,829.79
	<b>Total expenses</b>	<b>46,663.89</b>	<b>47,948.90</b>	<b>42,241.52</b>	<b>140,818.01</b>	<b>124,260.59</b>	<b>166,942.41</b>
IV	<b>Profit before tax</b>	<b>12,087.21</b>	<b>12,689.27</b>	<b>7,989.37</b>	<b>36,350.32</b>	<b>24,751.12</b>	<b>35,170.50</b>
V	<b>Tax expenses</b>						
	Current tax (including earlier years)	3,575.51	3,504.45	2,555.98	10,534.96	7,507.23	9,736.19
	Deferred tax credit	(222.70)	(324.79)	(443.87)	(1,049.79)	(985.09)	(890.21)
VI	<b>Profit after tax</b>	<b>8,734.40</b>	<b>9,509.61</b>	<b>5,877.26</b>	<b>26,865.15</b>	<b>18,228.98</b>	<b>26,324.52</b>
VII	<b>Other comprehensive income</b>						
	A (i) Items that will not be reclassified to statement of profit or loss	57.15	88.42	21.04	(140.20)	57.70	154.86
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(14.38)	(22.25)	(5.29)	35.29	(14.52)	(38.98)
	B (i) Items that will be reclassified to statement of profit or loss	-	-	-	-	-	-
	(ii) Income-tax relating to items that will be reclassified to statement of profit or loss	-	-	-	-	-	-
	<b>Total other comprehensive income</b>	<b>42.77</b>	<b>66.17</b>	<b>15.75</b>	<b>(104.91)</b>	<b>43.18</b>	<b>115.88</b>
VIII	<b>Total comprehensive income</b>	<b>8,777.17</b>	<b>9,575.78</b>	<b>5,893.01</b>	<b>26,760.24</b>	<b>18,272.16</b>	<b>26,440.40</b>
IX	Paid-up equity share capital (face value of ₹ 2 each)	5,368.55	5,368.15	5,363.70	5,368.55	5,363.70	5,363.90
X	Reserves (other equity)						243,521.77
XI	Earnings per share: (face value of ₹ 2 each) (not annualised except for the year ended 31 March 2023)						
	Basic (₹ per share)	3.25	3.54	2.25	10.01	7.12	10.16
	Diluted (₹ per share)	3.25	3.54	2.25	10.00	7.11	10.15

See accompanying notes to the standalone mandated financial results

(This space has been intentionally left blank)



SIGNED FOR  
IDENTIFICATION  
PURPOSES ONLY



**Global Health Limited****Notes to the unaudited standalone financial results:**

- 1 The above standalone financial results for the quarter and nine months period ended on 31 December 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 08 February 2024 and a limited review of the same has been carried out by the statutory auditors.
- 2 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The chief operating decision maker (CODM) examines the Company's performance from a service perspective and has identified the Healthcare services as single business segment. The Company is operating in India which constitutes a single geographical segment.
- 4 During the year ended 31 March 2023, the Company had completed its Initial Public Offer (IPO) of 65,641,952 equity shares of face value of ₹ 2 each for cash at a price of ₹ 336 per equity share (including a share premium of ₹ 334 per equity share) aggregating to ₹ 220,556.96 lakhs. This comprises of fresh issue of 14,880,952 equity shares aggregating up to ₹ 50,000.00 lakhs (fresh issue) and an offer for sale of 50,761,000 equity shares aggregating to ₹ 170,556.96 lakhs. The equity shares of the Company got listed at BSE Limited and National Stock Exchange of India Limited on 16 November 2022.

The utilisation of the initial public offer proceeds is summarised below:

(₹ in lakhs)			
Object of the issue as per prospectus	Utilisation planned as per prospectus*	Total utilised upto 31 December 2023	Amount pending for utilisation as at 31 December 2023 #
Investment in the form of debt, equity or repayment/prepayment of the borrowings in full or part in wholly owned subsidiaries Global Health Patliputra Private Limited and Medanta Holdings Private Limited	37,500.00	37,500.00	-
General corporate purposes	10,170.10	6,824.34	3,345.76

\* Net of share issue expense of ₹ 2,329.90 lakhs


#The above mentioned unutilised proceeds have been temporarily invested in deposits with banks.

- 5 During the quarter and nine months ended 31 December 2023, the Company has allotted 20,000 and 232,210 equity shares under the Company's Employee Stock Options Schemes on exercise of vested options by eligible employees.
- 6 During the quarter, the Company has executed definitive agreements with DLF Limited and incorporated a new entity namely, GHL Hospital Limited to set up a 400 bed multi-speciality hospital in Delhi.

For and on behalf of the Board of Directors of Global Health Limited

Place : Gurugram  
Date : 08 February 2024



  
Dr. Naresh Trehan  
Chairman and Managing Director



**SIGNED FOR  
IDENTIFICATION  
PURPOSES ONLY**

---

Walker Chandlok & Co LLP  
21st Floor, DLF Square  
Jacaranda Marg, DLF Phase II  
Gurgaon - 122 002  
India

T +91 124 462 8099  
F +91 124 462 8001

**Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Global Health Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended 31 December 2023 and the consolidated year to date results for the period 01 April 2023 to 31 December 2023, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



---

Chartered Accountants

Offices in Bengaluru, Chandigarh, Chennai, Gurugram, Hyderabad, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

---

Walker Chandlok & Co LLP is registered with limited liability with identification number AAC-2085 and its registered office at L-41 Connaught Circus, New Delhi, 110001, India

## Walker ChandioK & Co LLP

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker ChandioK & Co LLP  
Chartered Accountants  
Firm Registration No: 001076N/N500013

*Tarun*

**Tarun Gupta**  
Partner  
Membership No. 507892

UDIN: 24507892BKEISF8680

Place: Gurugram  
Date: 08 February 2024



# Walker Chandiook & Co LLP

Annexure 1 to the Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

## List of entities included in the Statement

S. No.	Name	Relationship with the Holding Company
1	Medanta Holdings Private Limited	Wholly owned subsidiary
2	Global Health Patliputra Private Limited	Wholly owned subsidiary
3	GHL Pharma & Diagnostic Private Limited (Formerly known as Global Health Pharmaceuticals Private Limited) (incorporated on 29 June 2022)	Wholly owned subsidiary
4	GHL Hospital Limited (incorporated on 11 December 2023)	Subsidiary



Global Health Limited

Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India  
Corporate Office: Medanta - The Medicity, Sector - 38, Gurgaon, Haryana - 122001, India  
CIN:L85110DL2004PLC128319

Tel: +91 124 483 4060; E-mail: compliance@medanta.org; Website: https://www.medanta.org

Statement of Consolidated Unaudited Financial Results for the quarter ended and nine months period ended 31 December 2023

(₹ in lakhs, unless otherwise stated)

S. No.	Particulars	Quarter ended			Nine months period ended		Year ended
		31 December 2023 (Unaudited)	30 September 2023 (Unaudited)	31 December 2022 (Unaudited)	31 December 2023 (Unaudited)	31 December 2022 (Unaudited)	31 March 2023 (Audited)
	<b>Income</b>						
I	Revenue from operations	83,260.17	84,393.92	69,432.21	244,958.05	199,082.65	269,424.83
II	Other income	2,193.11	2,075.05	1,190.39	6,414.07	3,650.84	6,491.48
	<b>Total income</b>	<b>85,453.28</b>	<b>86,468.97</b>	<b>70,622.60</b>	<b>251,372.12</b>	<b>202,733.49</b>	<b>275,916.31</b>
	<b>Expenses</b>						
III	Cost of materials consumed	17,223.95	17,441.24	14,384.67	51,116.88	42,051.81	57,112.47
	Purchases of stock-in-trade	1,813.18	1,997.24	1,360.12	5,640.26	3,955.02	5,573.78
	Changes in inventories of stock-in-trade	29.44	(80.53)	51.02	(195.29)	44.32	(157.76)
	Employee benefits expense	18,486.15	18,378.79	15,960.56	54,657.40	47,542.92	63,434.54
	Finance costs	1,767.92	2,008.89	2,067.40	5,568.41	5,743.90	7,791.93
	Depreciation and amortisation expense	4,398.21	4,290.98	3,875.37	12,727.49	11,196.48	14,991.48
	Impairment losses on financial assets	553.45	558.20	284.07	1,755.72	476.72	761.87
	Retainers and consultants fee	11,168.36	10,723.81	8,467.91	31,894.57	24,204.79	33,301.13
	Other expenses	12,775.95	14,089.98	12,926.54	39,805.60	35,896.41	48,177.84
	<b>Total expenses</b>	<b>68,216.81</b>	<b>69,408.60</b>	<b>59,377.66</b>	<b>202,971.04</b>	<b>171,112.37</b>	<b>230,987.28</b>
IV	<b>Profit before tax</b>	<b>17,236.47</b>	<b>17,060.37</b>	<b>11,244.94</b>	<b>48,401.08</b>	<b>31,621.12</b>	<b>44,929.03</b>
	Tax expenses						
	Current tax (including earlier years)	4,997.81	4,788.16	2,555.98	13,977.80	7,507.23	9,736.19
	Deferred tax charge/(credit)	(15.41)	(243.88)	627.58	(667.90)	1,613.23	2,584.91
V	<b>Profit after tax</b>	<b>12,354.07</b>	<b>12,516.09</b>	<b>8,061.38</b>	<b>35,071.18</b>	<b>22,500.66</b>	<b>32,607.93</b>
	<b>Other comprehensive Income</b>						
	A (i) Items that will not be reclassified to statement of profit or loss	68.19	119.88	33.46	(126.22)	77.58	186.37
	(ii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(16.19)	(24.00)	(7.32)	33.26	(18.00)	(44.21)
	B (i) Items that will be reclassified to statement of profit or loss	-	-	-	-	-	-
	(ii) Income-tax relating to items that will be reclassified to statement of profit or loss	-	-	-	-	-	-
VI	<b>Total other comprehensive income</b>	<b>52.00</b>	<b>95.88</b>	<b>26.14</b>	<b>(92.96)</b>	<b>59.58</b>	<b>142.16</b>
VII	<b>Total comprehensive income</b>	<b>12,406.07</b>	<b>12,611.97</b>	<b>8,087.52</b>	<b>34,978.22</b>	<b>22,560.24</b>	<b>32,750.09</b>
	<b>Profit after tax attributable to:</b>						
	(i) Owners of the Holding Company	12,364.07	12,516.09	8,061.38	35,081.18	22,500.66	32,607.93
	(ii) Non-controlling interests	(10.00)	-	-	(10.00)	-	-
	<b>Other comprehensive income attributable to:</b>						
	(i) Owners of the Holding Company	52.00	95.88	26.14	(92.96)	59.58	142.16
	(ii) Non-controlling interests	-	-	-	-	-	-
	<b>Total comprehensive income attributable to:</b>						
	(i) Owners of the Holding Company	12,416.07	12,611.97	8,087.52	34,988.22	22,560.24	32,750.09
	(ii) Non-controlling interests	(10.00)	-	-	(10.00)	-	-
VIII	Paid-up equity share capital (face value of ₹ 2 each)	5,368.55	5,368.15	5,363.70	5,368.55	5,363.70	5,363.90
IX	Reserves (other equity)						237,456.92
X	<b>Earnings per share (face value of ₹ 2 each)</b> (not annualised except for the year ended 31 March 2023)						
	Basic (₹ per share)	4.61	4.66	3.08	13.07	8.79	12.58
	Diluted (₹ per share)	4.60	4.66	3.08	13.06	8.78	12.57

See accompanying notes to the consolidated unaudited financial results

(This space has been intentionally left blank)



**SIGNED FOR  
IDENTIFICATION  
PURPOSES ONLY**



Global Health Limited

Notes to the consolidated unaudited financial results:

- 1 The above consolidated unaudited financial results of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred as 'the Group') for the quarter and nine months period ended 31 December 2023 has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 08 February 2024 and a limited review of the same has been carried out by its statutory auditors.
- 2 These consolidated unaudited financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 3 The chief operating decision maker (CODM) examines the Group's performance from a service perspective and has identified the 'Healthcare Services' as single business segment. The Group is operating in India which constitutes a single geographical segment. Accordingly, no other disclosures are required to be furnished per Ind AS 108 'Operating Segments'.
- 4 During the year ended 31 March 2023, the Holding Company had completed its Initial Public Offer ('IPO') of 65,641,952 equity shares of face value of ₹ 2 each for cash at a price of ₹ 336 per equity share (including a share premium of ₹ 334 per equity share) aggregating to ₹ 220,556.96 lakhs. This comprises of fresh issue of 14,880,952 equity shares aggregating up to ₹ 50,000.00 lakhs ('fresh issue') and an offer for sale of 50,761,000 equity shares aggregating to ₹ 170,556.96 lakhs. The equity shares of the Holding Company got listed with BSE Limited and National Stock Exchange of India Limited on 16 November 2022.

The utilisation of the initial public offer proceeds is summarised below:

Object of the issue as per prospectus	Utilisation planned as per prospectus*	Total utilised upto 31 December 2023	(₹ in lakhs)
			Amount pending for utilisation as 31 December 2023 #
Investment in the form of debt, equity or repayment/prepayment of the borrowings in full or part in wholly owned subsidiaries Global Health Patliputra Private Limited and Medanta Holdings Private Limited	37,500.00	37,500.00	-
General corporate purposes	10,170.10	6,824.34	3,345.76

\* Net of share issue expense of ₹ 2,329.90 lakhs

#The above mentioned unutilised proceeds have been temporarily invested in deposits with banks.


- 5 During the quarter and nine months ended 31 December 2023, the Holding Company has allotted 20,000 and 232,210 equity shares under the Holding Company's Employee Stock Options Schemes on exercise of vested options by eligible employees.
- 6 During the quarter, the Holding Company has executed definitive agreements with DLF Limited and incorporated a new entity namely, GHIL Hospital Limited to set up a 400 bed multi-speciality hospital in Delhi.

For and on behalf of the Board of Directors of Global Health Limited

Place: Gurugram  
Date : 08 February 2024



SIGNED FOR  
IDENTIFICATION  
PURPOSES ONLY

  
Dr. Naresh Trehan  
Chairman and Managing Director

